Objective Assessment of Facial Lipoatrophy Changes in a Cohort of HIV-Infected Patients Taking Combination Antiretroviral Therapy

REFERENCES

• Echavez M, Horstman W. Relationship between lipoatro-phy and quality of life. AIDS Read. 2005;15:369–375.
   PubMedGoogle Scholar
• Talmor M, Hoffman LA, LaTrenta GS. Facial atrophy in HIV-related fat redistribution syndrome: Anatomic evaluation and surgical reconstruction. Ann Plast Surg. 2002;49:11-17; discussion 117–118.
   PubMed Web of Science ®Google Scholar
• Martinez E, Garcia-Viejo MA, Blanch L, Gatell JM. Lipodys-trophy syndrome in patients with HIV infection: Quality of life issues. Drug Saf. 2001,24:157–166.
   PubMed Web of Science ®Google Scholar
• Power R, Tate HL, McGill SM, Taylor C. A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals. Sex Transm Infect. 2003; 79:137–141.
   PubMed Web of Science ®Google Scholar
• Gazzard B. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral ther-apy (2005). HIV Med. 2005;6(Suppl 2):1–61.
   Google Scholar
• John M, McKinnon EJ, James IR, Nolan DA, Herrmann SE, Moore CB, et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/ abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr 2003;33:29–33.
   PubMed Web of Science ®Google Scholar
• Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to aba-cavir: The MITOX Extension Study. AIDS. 2004;18:1029–1036.
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the man-agement of dyslipidemia and peripheral lipoatrophy. J Ac-quir Immune Defic Syndr 2003;33:22–28.
   PubMed Web of Science ®Google Scholar
• Valantin MA, Aubron-Olivier C, Ghosn J, Laglenne E, Pauchard M, Schoen H, et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected pa-tients: Results of the open-label study VEGA. AIDS. 2003; 17:2471–2477.
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Lysakova L, Brown S, Sibtain N, Healy J, Priest C, et al. A randomized open-label study of immediate ver-sus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV in-fection. HIV Med. 2004;5:82–87.
   PubMed Web of Science ®Google Scholar
• Lafaurie M, Dolivo M, Porcher R, Rudant J, Madelaine I, Molina JM. Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients. J Ac-quir Immune Defic Syndr 2005;38:393–398.
   PubMed Web of Science ®Google Scholar
• Jones DH, Carruthers A, Orentreich D, Brody HJ, Lai MY, Azen S, Van Dyke GS. Highly purified 1000-cSt sili-cone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy: An open pilot trial. Dermatol Surg. 2004;30:1279–1286.
   PubMed Web of Science ®Google Scholar
• Law M, Puls R, Cheng AK, Cooper DA, Carr A. Evalua-tion of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adults. Antiviral Ther 2006;11:179–186.
   PubMed Web of Science ®Google Scholar
• Wilson I, Snape L, Fright R, Nixon M. An investigation of laser scanning techniques for quantifying changes in facial soft-tissue volume. N Z Dent J 1997;93:110–113.
   PubMedGoogle Scholar
• Ferrario VF, Sforza C, Serrao G, Ciusa V, Dellavia C. Growth and aging of facial soft tissues: A computerized three-dimensional mesh diagram analysis. Clin Anat. 2003;16: 420–433.
   PubMed Web of Science ®Google Scholar
• Soncul M, Bamber MA. The reproducibility of the head position for a laser scan using a novel morphometric analy-sis for orthognathic surgery. Int J Oral Maxillofac Surg. 2000;29:86–90.
   PubMed Web of Science ®Google Scholar
• Wilks RJ. An optical system for measuring surface shapes for radiotherapy planning. Br J RadioL 1993;66:351–359.
   PubMed Web of Science ®Google Scholar
• Paton NI, Yang Y, Sitoh YY, Oo Tha N. Validation of three-dimensional laser scanning for the assessment of facial fat changes. HIV Med. 2007;8:498–503.
   PubMed Web of Science ®Google Scholar
• Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults: A case-control study. Lancet. 2003;361: 726–735.
   PubMed Web of Science ®Google Scholar
• Yang Y, Paton NI. Laser scanning as a tool for assessment of HIV-related facial lipoatrophy: Evaluation of accuracy and reproducibility. HIV Med. 2005;6:321–325.
   PubMed Web of Science ®Google Scholar
• Paton NI, Yang Y, Tha NO, Sitoh YY. Changes in facial fat in HIV-related lipoatrophy, wasting, and weight gain measured by magnetic resonance imaging. HIV Clin Trials. 2007;8:227–234.
   PubMed Web of Science ®Google Scholar
• Benn P, Sauret V, Cartledge J, Ruff C, Sabin CA, Moyle G, et al. Improvements in facial lipoatrophy at 48 weeks fol-lowing substitution of a thymidine analogue with tenofovir or abacavir: A randomized, open-label study in people with lipoatrophy and virological suppression on HAART. In: Program and abstracts of the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; No-vember 13–16, 2005; Dublin. Abstract 8.
   Google Scholar
• Law M, Puls R, Cheng AK, Cooper DA, Carr A. Evalua-tion of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adults. Antivir Ther 2006;11:179–186.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wilder-Smith A, Panchalingam A, Tha NO, Paton NI. Changes in body fat measured by DEXA in patients taking different formulations of stavudine. HIV Clin Trials. 2005;6:337–343.
   PubMed Web of Science ®Google Scholar
• Yang Y, Sitoh YY, Oo Tha N, Paton NI. Facial fat volume in HIV-infected patients with lipoatrophy. Antivir Ther 2005; 10:575–581.
   PubMed Web of Science ®Google Scholar
• van Griensven J, De Naeyer L, Mushi T, Ubarijoro S, Gashumba D, Gazille C, Zachariah R. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hyg. 2007;101:793–798.
   PubMed Web of Science ®Google Scholar
• Podzamczer D, Ferrer E, Sanchez P, Gatell JM, Crespo M, Fisac C, et al. Less lipoatrophy and better lipid pro-file with abacavir as compared to stavudine: 96-week re-sults of a randomized study. J Acquir Immune Defic Syndr 2007;44:139–147.
   PubMed Web of Science ®Google Scholar